Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2

Prior 2019 to work date entire world is seriously influenced by an appalling illness called COVID sickness [Coronavirus disease-2019 (COVID-19)] which is brought about by another strain of coronavirus known as severe acute respiratory syndrome-Coronavirus-2. This pandemic was first seen in the Hubei...

Descripción completa

Detalles Bibliográficos
Autores principales: Kumar, Avinash, Parihar, Arpana, Basha, S. Nisar, Panda, Udwesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300481/
http://dx.doi.org/10.1016/B978-0-323-91172-6.00005-4
_version_ 1784751220765753344
author Kumar, Avinash
Parihar, Arpana
Basha, S. Nisar
Panda, Udwesh
author_facet Kumar, Avinash
Parihar, Arpana
Basha, S. Nisar
Panda, Udwesh
author_sort Kumar, Avinash
collection PubMed
description Prior 2019 to work date entire world is seriously influenced by an appalling illness called COVID sickness [Coronavirus disease-2019 (COVID-19)] which is brought about by another strain of coronavirus known as severe acute respiratory syndrome-Coronavirus-2. This pandemic was first seen in the Hubei area in Wuhan city of China. To date above 170 million individuals have been influenced by this infection and more than 3 million individuals died. The race of finding specific therapeutic drugs and efficacious vaccine candidates is still going on to tackle the pandemic-associated morbidities. This chapter discussed different clinically accessible medications (remdesivir, hydroxychloroquine, azithromycin, etc.) and immunizations (mRNA-1273, Sputanik, Pfizer, etc.) which are either in use or under trial for the treatment of COVID-19.
format Online
Article
Text
id pubmed-9300481
institution National Center for Biotechnology Information
language English
publishDate 2022
record_format MEDLINE/PubMed
spelling pubmed-93004812022-07-21 Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2 Kumar, Avinash Parihar, Arpana Basha, S. Nisar Panda, Udwesh Computational Approaches for Novel Therapeutic and Diagnostic Designing to Mitigate SARS-CoV-2 Infection Article Prior 2019 to work date entire world is seriously influenced by an appalling illness called COVID sickness [Coronavirus disease-2019 (COVID-19)] which is brought about by another strain of coronavirus known as severe acute respiratory syndrome-Coronavirus-2. This pandemic was first seen in the Hubei area in Wuhan city of China. To date above 170 million individuals have been influenced by this infection and more than 3 million individuals died. The race of finding specific therapeutic drugs and efficacious vaccine candidates is still going on to tackle the pandemic-associated morbidities. This chapter discussed different clinically accessible medications (remdesivir, hydroxychloroquine, azithromycin, etc.) and immunizations (mRNA-1273, Sputanik, Pfizer, etc.) which are either in use or under trial for the treatment of COVID-19. 2022 2022-07-15 /pmc/articles/PMC9300481/ http://dx.doi.org/10.1016/B978-0-323-91172-6.00005-4 Text en Copyright © 2022 Elsevier Inc. All rights reserved. Since January 2020 Elsevier has created a COVID-19 resource centre with free information in English and Mandarin on the novel coronavirus COVID-19. The COVID-19 resource centre is hosted on Elsevier Connect, the company's public news and information website. Elsevier hereby grants permission to make all its COVID-19-related research that is available on the COVID-19 resource centre - including this research content - immediately available in PubMed Central and other publicly funded repositories, such as the WHO COVID database with rights for unrestricted research re-use and analyses in any form or by any means with acknowledgement of the original source. These permissions are granted for free by Elsevier for as long as the COVID-19 resource centre remains active.
spellingShingle Article
Kumar, Avinash
Parihar, Arpana
Basha, S. Nisar
Panda, Udwesh
Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2
title Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2
title_full Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2
title_fullStr Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2
title_full_unstemmed Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2
title_short Clinically available/under trial drugs and vaccines for treatment of SARS-COV-2
title_sort clinically available/under trial drugs and vaccines for treatment of sars-cov-2
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9300481/
http://dx.doi.org/10.1016/B978-0-323-91172-6.00005-4
work_keys_str_mv AT kumaravinash clinicallyavailableundertrialdrugsandvaccinesfortreatmentofsarscov2
AT parihararpana clinicallyavailableundertrialdrugsandvaccinesfortreatmentofsarscov2
AT bashasnisar clinicallyavailableundertrialdrugsandvaccinesfortreatmentofsarscov2
AT pandaudwesh clinicallyavailableundertrialdrugsandvaccinesfortreatmentofsarscov2

Ejemplares similares